Vascular Disease and Prostate Cancer: A Conflicting Association
Keywords:Carotid vascular disease, Coronary artery disease, Vascular disease, Prostate Cancer.
Background: To date, only a few studies have explored the relationship between vascular disease and Prostate Cancer (PCa), with conflicting results. The Aim of the research was to investigate the association of carotid vascular disease (CVD) or Coronary Artery disease (CAD) with PCa hormone-naive at initial diagnosis.
Methods: Retrospective analysis of 266 patients undergoing prostate biopsy at our institution between 2006 and 2009 was conducted. We examined associations of CVD or CAD in 133 patients with PCa diagnosis versus 133 age-matched controls. Men with incomplete data available, history of hormone therapy or chemotherapy, prostate or bladder surgery were excluded.
Results: CVD was significantly linked to PCa in all cases versus controls at initial diagnosis of PCa (OR 2.42, p < 0.05). Similarly CAD was significantly related to PCa at initial diagnosis (OR 1.88, p < 0.05).
Conclusions: In our study a significant relation was found between vascular damage and PCa hormone-naive at initial diagnosis. Further research should elucidate these associations in larger samples to confirm these relationships and to stabilize future prevention strategies.
Omalu BI, Hammers JL, Parwani AV, Balani J, Shakir A, Ness RB. Niger Is there an association between coronary atherosclerosis and carcinoma of the prostate in men aged 50 years and older? An autopsy and coroner based post-mortem study. J Clin Pract 2013; 16: 45-8.
Dreyer L, Olsen JH. Risk for non-smoking-related cancer in atherosclerotic patients. Cancer Epidemiol Biomarkers Prev 1999; 8: 915-8.
Stamatiou KN, Alevizos AG, Mihas K, Mariolis AD, Michalodimitrakis E, Sofras F. Associations between coronary heart disease, obesity and histological prostate cancer. Int Urol Nephrol 2007; 39: 197-201. http://dx.doi.org/10.1007/s11255-006-9010-z
Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep 2009; 57: 1-134.
Thomas JA, Gerber L, Bañez LL, Moreira DM, Rittmaster RS, Andriole GL, Freedland SJ. Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev 2012; 21: 576-81. http://dx.doi.org/10.1158/1055-9965.EPI-11-1017
Satariano WA, Ragland KE, Van Den Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer 1998; 83: 1180-8. http://dx.doi.org/10.1002/(SICI)1097-0142(19980915)83:6<1180::AID-CNCR18>3.0.CO;2-1
Fouad MN, Mayo CP, Funkhouser EM, Hall HI, Urban DA, Kiefe CI. Comorbidity independently predicted death in older prostate cancer patients, more of whom died with than from their disease. J Clin Epidemiol 2004; 57: 721-29. http://dx.doi.org/10.1016/j.jclinepi.2003.11.009
Groome PA, Rohland SL, Siemens DR, Brundage MD, Heaton J, Mackillop WJ. Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates. Cancer 2011; 117: 3943-52. http://dx.doi.org/10.1002/cncr.25984
Pereira LMN, Biolo A, Foppa M, da Rosa PR, Rohde LE, Clausell N. A prospective, comparative study on the early effects of local and remote radiation therapy on carotid intima-media thickness and vascular cellular adhesion molecule-1 in patients with head and neck and prostate tumors. Radiother Oncol 2011; 101: 449-53. http://dx.doi.org/10.1016/j.radonc.2010.03.026
Di Francesco S, Castellan P, Manco R, Tenaglia RL. Reciprocal cross-talk between Prostaglandin E2 and bone in prostate cancer: a current Review. Cent Eur J Urol 2011; 4: 9-12.
Touvier M, Fezeu L, Ahluwalia N, Julia C, Charnaux N, Sutton A, et al. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J Epidemiol 2013; 177: 3-13. http://dx.doi.org/10.1093/aje/kws359
Peiser L, Gordon S. The function of scavenger receptors expressed by macrophages and their role in the regulation of inflammation. Microbes Infect 2001; 3: 149-59. http://dx.doi.org/10.1016/S1286-4579(00)01362-9
Maier C, Vesovic Z, Bachmann N, Herkommer K, Braun AK, Surowy HM, et al. Germline mutations of the MSR1 gene in prostate cancer families from Germany. Hum Mutat 2006; 27: 98-102. http://dx.doi.org/10.1002/humu.20271
Rennert H, Zeigler-Johnson CM, Addya K, Finley MJ, Walker AH, Spangler E, et al. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, andMSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol. Biomarkers Prev 2005; 14: 949-57. http://dx.doi.org/10.1158/1055-9965.EPI-04-0637
Hope Q, Bullock S, Evans C, Meitz J, Hamel N, Edwards SM, et al. Cancer Research UK/British Association of Urological Surgeons' Section of Oncology Collaborators. Macrophage scavenger receptor 1 999C.T (R293X) mutation and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev 2005; 14: 397-402. http://dx.doi.org/10.1158/1055-9965.EPI-04-0202
Lindmark F, Jonsson BA, Bergh A, Stattin P, Zheng SL, Meyers DA, et al. Analysis of the macrophage scavenger receptor 1 gene in Swedish hereditary and sporadic prostate cancer. Prostate 2004; 59: 132-40. http://dx.doi.org/10.1002/pros.10367
Nupponen NN, Wallén MJ, Ponciano D, Robbins CM, Tammela TL, Vessella RL, et al. Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer. Genes Chromosomes Cancer 2004; 39: 119-25. http://dx.doi.org/10.1002/gcc.10308
Sun J, Hsu FC, Turner AR, Zheng SL, Chang BL, Liu W,
et al. Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk. Prostate 2006; 66: 728-37. http://dx.doi.org/10.1002/pros.20396
Hsing AW, Sakoda LC, Chen J, Chokkalingam AP, Sesterhenn I, Gao YT, et al. MSR1 variants and the risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Carcinogenesis 2007; 28: 2530-6. http://dx.doi.org/10.1093/carcin/bgm196
Beuten J, Gelfond JA, Franke JL, Shook S, Johnson-Pais TL, Thompson IM, Leach RJ. Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. Cancer Epidemiol Biomarkers Prev 2010; 19: 588-99. http://dx.doi.org/10.1158/1055-9965.EPI-09-0864
Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002; 32: 321-5. http://dx.doi.org/10.1038/ng994